Evaxion presents new preclinical data for CMV vaccine program EVX-V1 at IHW 2026

EVAX•2026-07-13

Data to inform future CMV candidate selection

Data are expected to guide antigen selection for a future broadly protective CMV vaccine candidate, a key step toward advancing the program.

New preclinical EVX-V1 data presented at IHW 2026

Evaxion disclosed new preclinical data for its EVX-V1 cytomegalovirus vaccine program, presented today at the International Herpesvirus Workshop 2026.

The results supported a multi-component vaccine approach, pointing to better control of infection, viral latency, and reactivation in animal studies.

Sources

Evaxion presents new preclinical data for CMV vaccine program EVX-V1 at IHW 2026

Sec

Evaxion presents new preclinical data for CMV vaccine program EVX-V1 at IHW 2026

Data to inform future CMV candidate selection

New preclinical EVX-V1 data presented at IHW 2026

Related News

Union Pacific Corp: Raymond James raises target price to $363 from $310

Ionis Pharmaceuticals announces availability of press release on ION337 ASCEND study in Dravet syndrome

Hamilton Lane Inc <HLNE.O>: BMO cuts target price to $94 from $102

Sources

Evaxion presents new preclinical data for CMV vaccine program EVX-V1 at IHW 2026

First Hawaiian to buy regional lender TriCo Bancshares

Radware Chief People Officer Rivkah Goldriech disposes of 750 common shares worth $24,000